OvaScience To Present At Upcoming Investor Conferences In September

WALTHAM, Mass.--(BUSINESS WIRE)--OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced that Harald Stock, Ph.D., President and Chief Executive Officer, will present a corporate overview at three upcoming conferences:

Baird 2016 Global Healthcare Conference

Date: Wednesday, September 7, 2016

Time: 7:55 a.m. ET

Location: New York, NY

Rodman & Renshaw 18th Annual Global Investment Conference

Date: Monday, September 12, 2016

Time: 3:25 p.m. ET

Location: New York, NY

Ladenburg Thalmann 2016 Healthcare Conference

Date: Tuesday, September 27, 2016

Time: 3:30 p.m. ET

Location: New York, NY

Live webcasts of the presentations can be accessed by visiting the Investors section of the Company’s website at www.ovascience.com. A replay of the webcasts will be archived on the OvaScience website for two weeks following each presentation.

About OvaScience

OvaScienceSM (NASDAQ: OVAS) is a global fertility company dedicated to improving treatment options for women around the world. OvaScience is discovering, developing and commercializing new fertility treatments because we believe women deserve more options. Each OvaScience treatment is based on the Company’s proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPCSM) cells – immature egg cells found inside the protective ovarian lining. The AUGMENTSM treatment, a fertility option specifically designed to improve egg health, is available in certain IVF clinics in select international regions. OvaScience has commenced a non-commercial preceptorship training program with the OvaPrimeSM treatment, which could increase a woman’s egg reserve, and is developing the OvaTureSM treatment, a potential next-generation IVF treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections. OvaScience treatments are not available in the U.S. For more information, please visit www.ovascience.com and www.augmenttreatment.com and connect with us on Twitter and Facebook.



Media and Investor Contact:
Jennifer Viera, 617-420-8748

Back to news